On November 12, 2018 Complix, a biopharmaceutical company developing a pipeline of transformative Cell Penetrating Alphabodies (CPABs) reported that its Chief Scientific Officer, Dr Yvonne McGrath, will be presenting recent developments on CPABs against intracellular targets at the 10th Annual PEGS Europe Meeting (Protein and Antibody Engineering Summit) in Lisbon Portugal, November 12-16 (Press release, Complix, NOV 12, 2018, View Source [SID1234531276]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In her presentation Dr McGrath will provide an update on Complix’ recent progress with respect to CAPBs acting on important intracellular cancer targets. In particular Dr McGrath will be showing results obtained with CPABs targeting the enhanceosome of the Wnt pathway, a key pathway involved in development of cancer and other major diseases.

Details of the talk are as follows:

Title: "Cell Penetrating Alphabodies to Access Undruggable Intracellular Targets"
Session: "Engineering Antibodies"
Time: November 14 at 09:05 CET

On November 12, 2018 Agilent Technologies Inc. (NYSE: A) reported the following webcast for the investment community (Press release, Agilent, NOV 12, 2018, http://www.agilent.com/about/newsroom/presrel/2018/12nov-gp18060.html [SID1234531275]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Evercore ISI HealthCONx
Boston Harbor Hotel, Boston, Massachusetts
Tuesday, November 27, 2018 at 2:00 p.m. ET
Mike McMullen, Agilent president and chief executive offic

On November 12, 2018 Johnson & Johnson (NYSE: JNJ) reported that it will participate in the Citi’s 2018 Global Healthcare Conference on Wednesday, December 5th, at the Lotte New York Palace Hotel in New York City (Press release, Johnson & Johnson, NOV 12, 2018, View Source [SID1234531274]). Joseph J. Wolk, Executive Vice President and Chief Financial Officer will represent the Company in a session scheduled at 10:15 a.m. (Eastern).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com.

A webcast replay will be available approximately two hours after the live webcast.

On November 12, 2018 Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic") reported that it will report its financial results for the third quarter ended September 30, 2018 on Wednesday November 14, 2018 after market close (Press release, ProMetic Life Sciences, NOV 12, 2018, https://resources.prometic.com/latest-content/prometic-to-report-its-third-quarter-2018-financial-results-and-hold-conference-call-webcast [SID1234531241]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Prometic will host a conference call at 11:00am (ET) on Thursday November 15, 2018. The telephone numbers to access the conference call are 1-888-231-8191 and 647-427-7450. An audio replay of the call will be available as of Thursday November 15, 2018 at 2:00pm (ET). The numbers to access the audio replay are 416-849-0833 and 1-855-859-2056 using the following password (1190238).

On November 12, 2018 Gilead Sciences, Inc. (Nasdaq: GILD) reported that Robin L. Washington, Gilead’s Executive Vice President and Chief Financial Officer, and John McHutchison, AO, MD, Gilead’s Chief Scientific Officer and Head of Research & Development, will participate in a fireside chat at the Evercore ISI HealthCONx Conference in Boston on Tuesday, November 27 at 9:30 a.m. Eastern Time (Press release, Gilead Sciences, NOV 12, 2018, View Source;p=irol-newsArticle&ID=2376801 [SID1234531240]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The audio portion of the fireside chat will be accessible live through the company’s Investors page at www.gilead.com/investors. Please connect to the company’s website at least 15 minutes prior to the start of the presentation to ensure adequate time for any software download that may be required to listen to the webcast. The replay will be available for 14 days following the presentation.